Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for irritable bowel syndrome
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on irritable bowel syndrome or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on irritable bowel syndrome and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
, Charlotte, North Carolina, USA. Correspondence: Brian E. Lacy, PhD, MD, FACG. E-mail: . SUPPLEMENTARY MATERIAL accompanies this paper at . The American Journal of Gastroenterology: doi: 10.14309/ajg.0000000000001036 Free Metrics Abstract Irritablebowelsyndrome (IBS) is a highly prevalent, chronic disorder that significantly reduces patients' quality of life. Advances in diagnostic testing and in therapeutic options for patients with IBS led to the development of this first-ever American College (...) (IBS) is a chronic, often debilitating, and highly prevalent disorder of gut-brain interaction (previously called functional gastrointestinal [GI] disorders) ( ). In clinical practice, IBS is characterized by symptoms of recurrent abdominal pain and disordered defecation ( ). The Rome IV criteria, derived by consensus from a multinational group of experts in the field of disorders of gut-brain interaction, can be used to diagnose IBS for both clinical and research purposes ( ). Patients with IBS
Tenapanor (Ibsrela) - irritablebowelsyndrome Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1, 2012
Pharmacologic Treatments for IrritableBowelSyndrome: an Umbrella Systematic Review Pharmacologic Treatments for IrritableBowelSyndrome: an Umbrella Systematic Review | Journal of Gastrointestinal and Liver Diseases Abstract viewed - 0 times PDF downloaded - 0 times Supplementary File downloaded - 0 times License This work is licensed under a . Affiliations Min Chen Colorectal Department/ Clinical Medicine College, Hospital of Chengdu University of Traditional Chinese Medicine, Chendu, China (...) DOI Abstract Background and Aims: Multiple pharmacologic treatments are available for the management of irritablebowelsyndrome (IBS), and a large body of evidence has been presented. However, the strength and credibility of the evidence have not been comprehensively evaluated. We aimed to review the systematic reviews and meta- analyses of pharmacologic treatments for IBS and evaluate the credibility of the findings. Methods: We searched MEDLINE, Embase, and Cochrane library from inception
In irritablebowelsyndrome, fecal microbiota transplantation improved symptoms at 3 months. El-Salhy M, Hatlebakk JG, Gilja OH, Bråthen Kristoffersen A, Hausken T. Efficacy of faecal microbiota transplantation for patients with irritablebowelsyndrome in a randomised, double-blind, placebo-controlled study. Gut. 2020;69:859-67. 31852769.
, and dysbiosis is associated with a variety of gastrointestinaldisorders, including celiac disease (CD) and irritablebowelsyndrome (IBS). The distinction between IBS and non-celiac gluten sensitivity (NCGS) is unclear, and it is conceivable that the gut microbiota profile of these patients may overlap. To our knowledge, no existing literature has evaluated the microbial characteristics in CD, IBS, and NCGS. Hence, this systematic review aims to compare the gut microbiota profile in these three diagnoses (...) Comparison of gut microbiota profile in celiac disease, non-celiac gluten sensitivity and irritablebowelsyndrome: A systematic review Comparison of gut microbiota profile in celiac disease, non-celiac gluten sensitivity and irritablebowelsyndrome: A systematic review EISSN 2148-5607 Turkish Journal of Gastroenterology Toggle navigation Turkish Journal of Gastroenterology HIGHLY CITED ARTICLES By: Aydin, M. Merve; Akcali, Kamil Can By: Besheer, Tarek; Arafa, Mona M.; Abd El-Maksoud, Mohamed
Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With IrritableBowelSyndrome Peppermint oil is frequently used to treat irritablebowelsyndrome (IBS), despite a lack of evidence for efficacy from high-quality controlled trials. We studied the efficacy and safety of small-intestinal-release peppermint oil in patients with IBS and explored the effects of targeted ileocolonic-release peppermint oil.We performed a double-blind trial of 190 patients with IBS (...) (according to Rome IV criteria) at 4 hospitals in The Netherlands from August 2016 through March 2018; 189 patients were included in the intent-to-treat analysis (mean age, 34.0 years; 77.8% female; 57.7% in primary care), and 178 completed the study. Patients were randomly assigned to groups given 182 mg small-intestinal-release peppermint oil, 182 mg ileocolonic-release peppermint oil, or placebo for 8 weeks. The primary endpoint was abdominal pain response, as defined by the US Food and Drug
BE, Harris LA, et al. Am J Gastroenterol. 2019; 114(1):21-39. 2. Ruepert L, Quartero AO, de Wit NJ, et al. Cochrane Database Syst Rev. 2011; (8):CD003460. 3. Ford AC, Quigley EM, Lacy BE, et al. Am J Gastroenterol. 2014; 109(9):1350-65. 4. Moayyedi P, Andrews CN, MacQueen G, et al. J Can Assoc Gastroenterol. 2019; 2(1):6-29. 5. Canadian Digestive Health Foundation. IrritableBowelSyndrome. Available at: https://cdhf.ca/digestive-disorders/irritable-bowel-syndrome-ibs/what-is-irritable- bowel-syndrome (...) January 20, 2020 But I am not Depressed: Antidepressants for IrritableBowelSyndrome Clinical Question: Do antidepressant medications improve irritablebowelsyndrome (IBS) symptoms? Bottom Line: Both tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) may improve overall IBS symptoms. About 55% of patients treated with TCAs or SSRIs will benefit compared to ~35% with placebo. Only TCAs improve abdominal pain for ~60% of patients compared to ~30% with placebo. TCA
in IBS. Larger, more rigorously conducted trials of FMT in IBS are needed. M El-Salhy et al. Expert Rev Gastroenterol Hepatol 12 (5), 439-445. May 2018. PMID 29493330. - Review Irritablebowelsyndrome (IBS) is a widespread gastrointestinaldisorder affecting 11.2% of the world adult population. The intestinal microbiome is thought to play a piv … Show more similar articles Associated data ClinicalTrials.gov/NCT03822299 Actions LinkOut - more resources Full Text Sources Medical Full-text links [x] [x (...) bacterial profiles changed also significantly in the groups received FMT. The FMT adverse events were mild self-limiting gastrointestinal symptoms. Conclusions: FMT is an effective treatment for patients with IBS. Utilising a well-defined donor with a normal DI and favourable specific microbial signature is essential for successful FMT. The response to FMT increases with the dose. Trial registration www.clinicaltrials.gov ( ) and www.cristin.no (ID657402). Keywords: colonic microflora; irritablebowel
[Effect of healthy eating before intervention with a low FODMAP diet in pediatric patients with irritablebowelsyndrome]. Background: a diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) may be effective in the treatment of pediatric patients with irritablebowelsyndrome (IBS). Its complexity and side effects make it a secondary therapeutic alternative. Objective: to demonstrate that nutritional education, aimed at optimizing the diet of children (...) with IBS, is able to improve gastrointestinal symptoms of children without following a diet low in FODMAP. Methods: prospective intervention study. Changes in gastrointestinal symptoms were analyzed by means of the Pediatric Quality of Life Inventory™ Gastrointestinal Symptoms (PedsQL™ GI Symptoms), after receiving nutritional education based on a healthy diet. Likewise, anthropometric changes and dietary habits were analyzed. Results: twenty-one patients were included (12 girls) with a mean age
Tenapanor (Ibsrela) - irritablebowelsyndrome with constipation in adults Drug Approval Package: IBSRELA U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: IBSRELA Company: Ardelyx, Inc. Application Number: 211801 Approval Date: 09/12/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF) (PDF) (PDF
Summary of Recommendations of the American Gastroenterological Association on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant IrritableBowelSyndrome in Adults Statement Strength of recommendation Quality of evidence Recommendation 1: In patients presenting with chronic diarrhea, the AGA suggests the use of either fecal calprotectin or fecal lactoferrin to screen for IBD . Conditional Low Recommendation 2: In patients presenting with chronic diarrhea, the AGA suggests (...) Carrasco-Labra, A., Lytvyn, L., Falck-Ytter, Y. et al. AGA technical review on the evaluation of functional diarrhea and diarrhea-predominant irritablebowelsyndrome in adults (IBS-D). Gastroenterology . 2019 ; 157 : 859–880 | | | | | 5 Traveler’s Health. Travelers’ diarrhea. Centers for Disease Control and Prevention website. ( Available at: ) Date accessed: January 27, 2019 | 6 Riddle, M.S., Connor, B.A., Beeching, N.J. et al. Guidelines for the prevention and treatment of travelers' diarrhea
Lyophilized versus Frozen Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection, Inflammatory BowelDisease, and IrritableBowelSyndrome: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Lyophilized versus Frozen Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection, Inflammatory BowelDisease, and IrritableBowelSyndrome: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you (...) need Lyophilized versus Frozen Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection, Inflammatory BowelDisease, and IrritableBowelSyndrome: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Lyophilized versus Frozen Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection, Inflammatory BowelDisease, and IrritableBowelSyndrome: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Last updated: August 14, 2019 Project
Efficacy and Safety of Eluxadoline in Patients With IrritableBowelSyndrome With Diarrhea Who Report Inadequate Symptom Control With Loperamide: RELIEF Phase 4 Study Irritablebowelsyndrome with diarrhea (IBS-D) is a functional gastrointestinaldisorder with limited effective treatment options. We evaluated the efficacy and safety of eluxadoline in patients with IBS-D who reported inadequate symptom control with prior loperamide.Three hundred forty-six adults with IBS-D (Rome III criteria (...) ) were randomly assigned to placebo or eluxadoline 100 mg twice daily for 12 weeks. Patients recorded daily IBS-D symptoms, including worst abdominal pain (WAP) and stool consistency (through Bristol Stool Scale). The primary endpoint was proportion of composite responders, defined as patients who met daily composite response criteria (≥40% WAP improvement and <5 Bristol Stool Scale score) for at least 50% of treatment days, and recorded ≥60 days of diary entries over the 12-week period.Over 12 weeks